Sai Life Sciences Ltd.
NSE: SAILIFESai Life Sciences Ltd.: A 30-second snapshot
Sai Life Sciences (SAILIFE) is a pharma CDMO listed on NSE, trading at ₹1,090.9 — up 50.4% over the past 12 months and 14.9% over three months, with current price sitting above both the 50-DMA (₹1,019.8) and 200-DMA (₹915.7). FY26 reported 29% revenue growth and 109% PAT increase, though the 5-year revenue CAGR of 6.6% indicates that recent growth is a sharp step-up from historical pace. Trailing PE of 67.9x and D/E of 11.6 are the two most prominent structural data points.
P/E
67.9
Forward P/E
43.3
ROE
+15.1%
Debt / Equity
11.61
Profit Margin
+15.6%
Div. Yield
—
5Y ROE > 15%
0/5
5Y FCF > 0
2/5
Quality
58/100
News
8 headlines · 5 positive · 1 negative
SAILIFE: FY 2026 delivered robust growth, with large pharma driving revenue and major CapEx planned - TradingView
TradingView
SAILIFE: Strong FY 2026 growth, rising CapEx, and deepening large pharma partnerships drive outlook - TradingView
TradingView
SAILIFE: FY26 saw 29% revenue growth, 109% PAT increase, and expanded Capex for future capacity - TradingView
TradingView
SAILIFE: Strong revenue and profit growth in FY26, with full utilization of IPO proceeds - TradingView
TradingView
Sai Life Sciences Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026 - marketscreener.com
marketscreener.com
Recent context
- ·FY26 earnings release (May 2026) reported 29% revenue growth and 109% PAT increase, with management citing large-pharma client deepening and expanded CapEx for future capacity — covered positively across 5 of 8 news items in the dataset.
- ·A planned CapEx ramp signals capacity build-out; this is consistent with the elevated D/E and low historical FCF, as growth investment precedes cash generation in CDMO business models.
- ·Analyst coverage across 6 analysts shows a mean rating of 1.33 on a 1–5 scale (lower = more constructive).
Strengths
- +Among 6 pharma/healthcare peers tracked, SAILIFE ranks 1st on ROE at 15.1% — ahead of Cipla (11.7%) and Dr. Reddys (11.8%), the two large-cap comparables with available ROE data.
- +FY26 results show 109% PAT growth and 29% revenue growth year-on-year, with news citing full utilisation of IPO proceeds and expanded CapEx directed at large-pharma partnerships.
- +Debt trend is reported as falling, and forward PE of 43.3x implies the market is pricing in a meaningful near-term earnings increase relative to the trailing multiple of 67.9x.
- +Price is 4.3% below the 52-week high with RSI at 58.6 (neutral range), above both key moving averages — the technical picture reflects an extended uptrend without an overbought reading.
Weaknesses
- −D/E of 11.6 is elevated relative to capital-light pharma peers; at a trailing PE of 67.9x, there is limited valuation cushion if operating cash flow does not convert reliably.
- −FCF positive in only 2 of the available years and 0 ROE years historically above 15% indicate that the current ROE of 15.1% and the FY26 profit surge have not yet established a sustained track record.
- −5-year revenue CAGR of 6.6% is modest; the FY26 step-up to 29% growth represents a sharp departure — whether that pace is structurally repeatable or tied to a concentrated client ramp remains unresolved in the data.
- −Quality score of 47/100 (ranked 3rd of 6 peers) and consistency score of 60 suggest mid-tier fundamental durability compared to the sector cohort.
Open questions
- ?Does the 29% revenue growth in FY26 reflect a structural win with large-pharma clients or a one-time project ramp — and what does the order-book or revenue-mix data suggest about repeatability?
- ?Given D/E of 11.6 and FCF positive in only 2 of the available years, how does the planned CapEx affect the debt-service coverage ratio over the next 2–3 years?
- ?The 5-year earnings CAGR of 17.6% is materially higher than the 5-year revenue CAGR of 6.6% — what has driven margin expansion, and is that margin lever still available at current operating scale?
- ?How does SAILIFE compare to other listed CDMO peers (outside this 6-peer pharma grouping) on revenue per employee, asset turns, and client concentration — metrics not captured in the current dataset?
Peer comparison: Pharma
Ranks 3 of 6 on quality| Symbol | Name | P/E | ROE | Quality |
|---|---|---|---|---|
| SAILIFE | Sai Life Sciences Ltd.You're viewing | 67.9 | +15.1% | 47 |
| Industry avg | across 5 peers | 46.9 | +11.8% | 37 |
| MAXHEALTH | Max Healthcare Institute Ltd. | 72.4 | — | 54 |
| SUNPHARMA | Sun Pharmaceutical Industries Ltd. | 41.3 | — | 50 |
| APOLLOHOSP | Apollo Hospitals Enterprise Ltd. | 64.5 | — | 42 |
| CIPLA | Cipla Ltd. | 29.8 | +11.7% | 24 |
| DRREDDY | Dr. Reddy's Laboratories Ltd. | 26.7 | +11.8% | 17 |
Technical state
Current price
₹1,090.90
SMA 50
₹1,019.84
SMA 200
₹915.70
RSI (14)
58.6 (neutral)
From 52w high
-4.3%
1Y return
+50.4%
3M return
+15.0%
50-DMA
Above
200-DMA
Above
Algorithmic support levels
Risk flags
- highDebt-to-equity of 11.6 is well above typical pharma/CDMO peers. While the debt trend is reported as falling, this leverage level at a trailing PE of 67.9 leaves limited margin for any operating or cash-flow deterioration.
- highFCF positive in only 2 of the available years and ROE years above 15% is 0 historically — current ROE of 15.1% sits exactly at the threshold but has not been sustained across the earnings history, signalling inconsistent capital returns relative to the leverage carried.
- mediumTrailing PE of 67.9 ranks SAILIFE 5th-most-expensive of 6 sector peers on valuation (only MAXHEALTH at 72.4 is higher); forward PE of 43.3 implies a material earnings ramp is already priced in. Cipla trades at 29.8x and Dr. Reddys at 26.7x.
- low5-year revenue CAGR of 6.6% is modest; quality score of 47/100 is mid-tier relative to peers. Consistency score of 60 reflects uneven historical profitability.
Cross-section contradictions
- Price is up 50.4% over 12 months and sits only 4.3% below the 52-week high, yet FCF has been positive in only 2 of the available years and ROE has not historically cleared 15% — price momentum and balance-sheet durability are pointing in opposite directions.
- FY26 news flow cites 29% revenue growth and 109% PAT increase, but the 5-year revenue CAGR stands at only 6.6%, suggesting the recent year was a sharp departure from the longer-term growth trend — durability of FY26 acceleration is unresolved.
For informational purposes only. Not investment advice. VivaTrades is not a SEBI-registered Investment Adviser or Research Analyst. Market data sourced from public feeds; consult a registered adviser before any investment decision.
Fundamentals & technicals: refreshed 25 Jun 2026 · refreshed daily at 01:00 IST
AI synthesis (narrative, snapshot, strengths/weaknesses, peer ranking): generated 17 May 2026 · rotates through NIFTY 500 every ~5 days